Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Of course if they don't get the money to get out of debt and conduct the research they will go bankrupt. I mentioned in an earlier post that the likelihood is that they will not make it.
I don't know how long clinical trials for dermatological cancer treatments take and they would need to wait until success is shown with animals. Overall, it will take at least 3 - 5 years from now to see an approval for use in humans. My guess is that it will be at least a year before testing is completed on animals.
Put your shares in a safety deposit box and open it up in a few years. This stock is not for the impatient.
We have invested in a startup biotech. They all lack for money and many go bankrupt. They dilute and borrow money incessantly. If what they have is perceived to be of value they will get the money needed to at least run initial clinical trials. If those trials are successful then more money will roll in. Look at PIRS, as an example. They started from nothing, have nothing approved, lose tens of millions of dollars a year but have product that is perceived as potentially generating billions of dollars in revenue. They have forged relationships with huge rx companies who have paid them many millions in advance just to do the clinical research on PIRS' products because they stand to gain from the relationship. If the products are not approved by the FDA or any other approval body the company will be worth zero. They have much more money than RDGL because their products will be in higher demand and they represent a novel class of drugs, i.e., an entirely new way of treating deadly diseases.
There is no need to complain about RDGL. If one is unwilling to lose their money, not just lose some money but all of it, that person has invested in the wrong stock. This is a very high risk and speculative venture that has a reasonable if not good chance of failing. If it is successful one stands to make a lot of money. It's a simple formula that is only painful if one is unwilling to take the risk and at the same time is invested in the stock.
I'm a former FDA employee and large shareholder. Let's be clear that it was approved as a device, not approved for use in animals at this time. They still need to show safety and efficacy via its clinical trials, as stated in their press release.
As you may recall, I have 15 million reasons for him doing so! I hope he and his advisors can make it happen, as do we all.
Why do you think this is not on the ABHI website? What is Kevin's incentive/disincentive to get ABHI relisted, if it's even possible?
[Deleted]
Seems that a lot of people do, at least about liking and trusting him. I just counter the over-the-top wishful thinking that has been prevalent on this board for months. Just one or two other people are willing to do that, both of whom are also shareholders. We need all perspectives represented without the prospect of facing backlash from other posters. I'm waiting and hoping to be made wrong but I'm unwilling to have my eyes wide shut. Feel free to put me on ignore.
Remember people predicting when the fins would come out? First by Halloween, then by Thanksgiving, then by the end of the year. Trying to predict what will happen with ABHI is like trying to predict who will win the 2024 Presidential election. One would have the same chance of being right with either.
Kevin is just a great guy. Always follows through with what he says. Never messes with the minds or portfolios of his investors. Who couldn't admire and fall head over heels for a guy like that?
He said that the financials would be released at the end of the 2017 and the company would be up-to-date. I may be in the dark about that, but I don't think it happened. He also releases meaningless fluff in his press releases. And that we'd see great things happening with Kaseya during the first quarter of 2018.
I'll believe what comes out of his mouth when I see it. And only then. So far he's been totally FOS.
While true it doesn't explain what happened in the years prior to Kevin getting involved with ABHI (and then ABHI signing an agreement with PC Drivers) when he had his own company (Voosh) to market and sell Veloxum software. PC Drivers had/has allegedly 4M customers. Kevin's story and software began years before ABHI.
Looking at the current situation throwing $15K into ABHI was insane. But if you read back over the last few months of messages on the board and videos and news posted by Kevin, then at the time it seemed like ABHI would take off. That's why I'm so pissed at this turn of events, as you might imagine. He may be a great guy but I'm more concerned with his abilities as a CEO. Now I can only hope for the best.
I've invested large amounts of money in tiny stocks (although not as tiny as this one). Some have paid off extremely well. Others have gone bankrupt. The idea is to have more do extremely well than go bankrupt.
Why do you "like" him? I neither like or dislike him but am angry with his performance. I have $15K into this company and while I bitch about him I do hope that he can transform himself into a CEO that can make great things happen, especially getting us relisted. I hope that the seemingly positive things going on at the moment benefit all of us, not just Kevin and his foundation.
Yes, but you aren't selling it to the public so you can say anything you want to anyone you want. It is different when you are the manufacturer and subtly making claims that your CBD oil supplement is being used by people to help with ED. The implication is that it is benefiting them or else why even mention it? I don't want to make a big deal about this just to say it's a concern. I've written to UBQU about it their response from them on my concerns about the gummies was "Fair enough, thanks for the feedback." I appreciated their response and I hope they well aware of what will and won't raise a red flag for the regulators. I don't want to belabor this as it may turn out to be nothing.
Wow! I can't believe what they say on the webpage about the CBD oil for pets.
"What do pet owners use CannazALL Pets™ for?
Anxiety | Arthritis | Allergies | Cancer | Digestive Issues | Seizures | Inflammation | Joint & Mobility Issues | Pain | Homeostasis"
Although they follow that up with we are not making a structure function claim it sure sounds like it to me regardless of their disclaimer. It's like selling green tea extract and saying that people use it to treat cancer, with the not so subtle insinuation that if you use the extract it will help you with your cancer. Seems way to close to the edge of what will be acceptable to the FDA, if it gets on the Agency's radar and it rises to the level of something whey would want to take action.
I wonder if UBQU has anyone working for or with their company that helps them evaluate their compliance with FDA regulations when it comes to supplements.
It will be interesting to see what they say about their gummies to be administered to children several times a day, dosage and why one would even want to do so.
I hope I am wrong about my concerns.
It's comments like that by Kevin that leads me to believe that he is both a terrible manager, leader, CEO and businessman. Kevin is the CEO of the company and he hired people to help his company get current. He failed and his consultants failed in doing their due diligence to assure SEC compliance. To push blame on the former CEO is the hallmark of a weak and clueless CEO. He has not shown himself as growing into his new role.
On a related note, in the years during which he did control the patent he was unsuccessful in marketing and selling his software. He first aligned himself with a POS company like ABHI. Now, although he is the CEO of ABHI, he needs the help of Bravatek to sell software that given what he has said consumers and corporate IT departments should be banging down doors to purchase. Why is that, why does he need others' help, given that his software is reportedly (by him) so revolutionary? This means perhaps half of revenues will go to Bravatek. Pink sheets (now gray) are often a place where people who have the mentality of a small business owner (and in this case one who has not been a very good one) get to be a publicly traded company. I hope we trade again so we can get back to my breakeven of .001 and maybe, beyond.
Does anyone know if UBQU has publicly available independent lab data on the purity and CBD content of their products?
Thank you for your permission. Now I can sleep well tonight.
We shouldn't be in this predicament. That is not forgivable.
And for the same reason I'm not selling my shares. Not worth getting $4500 back when if the stock gets relisted we stand to make a fortune IF everything Kevin has been saying the last few months is true and IF BVTK can really help ABHI get its software marketed. And then there's Kaseya that is ALLEGEDLY incorporating Veloxum into their software should a client elect, after a trial period, to subscribe to that service.
I hope so too but it is highly unlikely that Kevin has much insight as to the future of the company with regards to being relisted. Remember, this is the guy that didn't think (and his hired hands didn't think) to check to make sure they were in compliance with the SEC. That is the first thing I would do if I was taking over a publicly traded company. Inexcusable.
So why would you want to by more at .0001 if you're unsure that it will resume trading? It is a gamble for sure and is why I'm holding onto my shares.
They can be sold for .0003 (although not at this second; last trade .0002). Help me understand why I would sell them to you for .0001. Why even post something so ridiculous?
Difficult for me to feel solid here when we have a non-trading stock, a CEO who got us into this situation in the first place and a difficult although not impossible road ahead to relisting.
HEMA and ZMTP are my two largest holdings. That so many people are unaware of both companies especially given that they are potential blockbuster stocks is beyond belief. That will change. This board is about HEMA so this will be my last time mentioning ZMTP.
Do you have a sense of the potential market cap for HEMA? It will grow over time but I wonder what its long-term potential (3 - 5 years out, let's say) might be.
2017 Financial Report Released Today
https://finance.yahoo.com/news/hemacare-reports-full-2017-results-130000086.html
Outstanding results for 2017. I can't believe how few shares trade in such a profitable company with millions in cash and an extraordinarily bright future. I can't wait until the day when a 100 share trade doesn't cause the stock to move .80 in one direction or the other.
A misunderstanding. I thought you meant the EPA was using its test to prove the value of ABHI's software, not that ABHI was going to use the EPA measurement test to show the value of Veloxum. Thanks for the clarification.
> I’m counting on the EPA’s own test to prove the product works
EPA is looking at how much energy servers use and how servers could be optimized so that energy use may be reduced. Each vendor, e.g., AmbiCom, would need to demonstrate that they have a software solution. EPA's test will not "prove" that Veloxum works. Perhaps you are inferring something from what Kevin said that I am missing.
EPA's own test? Link?
Perhaps I was not being clear. The white paper is excellent and useful. It's how they used it by transmitting it to the White House that was, in my opinion, a wasted effort. Again, a MOOT point if we don't get relisted. Then we have to see how Kevin gets his software sold.
My day, too.
> fins were put on hold until gold was struck (patent)
I hear you but putting the reports on hold meant being out of compliance with the SEC resulting in delisting. Doesn't matter whether they had gold or not, they needed to respond to the SEC.
AmbiCom got flak because they did not adhere to SEC regulations, not because the SEC is getting hard on penny stocks.
"The white paper goes to the very top of the executive branch"
That would be the President. How do you know this? How is this even remotely possible? I'll answer that last question - it's not.
Yes, it's marketing 101 but that means to media/public/corporate. In government it's making connections with decision makers that are to be found in each Department and Agency. You don't send a white paper to the President. We want something to get done and with everything going on in any administration something like a white paper will be a low priority. At best, it would be routed to the Departments and Agencies within government but that is unlikely because then you have to circulate every white paper that comes into the White House. This is not done because it gives the appearance of favoritism to a particular vendor and there are likely thousands of requests/papers that come into the White House on a regular basis.
Bravatek's CEO allegedly has millions in contracts with the government. Using those relationships is the way to get heard, not sending a white paper to the White House.
I'll stop because for the fifth time, it's all meaningless unless we get relisted.
Okay. The white paper "news" has been posted at least 50 times on this board to give the impression that ABHI would have a chance at a huge government contract because of it. It was nonsense then and now. Regardless of what the software can do, unless the company gets relisted and can execute a well-thought out business plan we're kaput.
That is not how one gets a contract with the government. If Bravatek/AmbiCom want to publish their paper in a peer-reviewed journal or use it as a marketing tool with interested companies then great. To send the white paper to any Agency in the Federal government, never mind the White House (I'm sure Trump woke up even earlier than usual to read it), is a waste of time. One includes a White Paper and any other information including references and a demonstration of one's software (if requested) to an Agency as a part of a response to a request for proposal.
As the CEO Kevin was responsible for assuring all papers were filed on time with the SEC. Period.
Agreed. Huge risk with unpredictable gain. But we're in so we'll see how things play out.
Changing the share structure is further down on the list of things they need to get done. At some point, pending the company becoming profitable, it would be great for them to reduce the share count dramatically. A buy back would be nice.